No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma.

Abstract:

INTRODUCTION:Cancer is a major risk factor for developing venous thromboembolism (VTE). Plasma hypercoagulability is an established risk factor for cancer-related VTE. In addition, thrombocytosis and hyperreactive platelets have been implicated in VTE and cancer progression. Cirrhosis is associated with changes in platelet number and function. The platelet activation status of patients with cirrhosis and hepatocellular carcinoma has not yet been established. Here we assessed the platelet activation status in patients with hepatitis-related cirrhosis in presence or absence of HCC. MATERIALS AND METHODS:We performed a cross-sectional study including thirty-eight consecutive patients with hepatitis B- or C- related liver cirrhosis in presence or absence of HCC. We studied basal and agonist-induced platelet activation using flow cytometry. In addition, we studied the plasma levels of von Willebrand factor (VWF) and the VWF-cleaving protease ADAMTS13. Twenty healthy volunteers served as controls. RESULTS:We found no evidence of basal platelet activation in patients with cirrhosis compared to controls. However, we found reduced agonist-induced platelet activation in patients. No differences in the basal and agonist-induced platelets activation status between patients with or without HCC were detected. Plasma levels of VWF were increased and the levels of ADAMTS13 activity were decreased in patients compared to controls. No differences between the levels of VWF and ADAMTS13 in patients with or without HCC were detected. CONCLUSIONS:HCC development or recurrence in patients with hepatitis B- or C-related cirrhosis does not appear to be associated with platelet activation and changes in pivotal proteins in primary hemostasis.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Alkozai EM,Porte RJ,Adelmeijer J,Zanetto A,Simioni P,Senzolo M,Lisman T

doi

10.1016/j.thromres.2014.11.016

subject

Has Abstract

pub_date

2015-02-01 00:00:00

pages

292-7

issue

2

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(14)00625-2

journal_volume

135

pub_type

杂志文章
  • Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status.

    abstract:INTRODUCTION:Antithrombin (AT), protein C (PC) and protein S (PS) deficiencies are risk factors for venous thromboembolism. Overlapping values between heterozygous carriers and normal individuals often make a correct classification of a deficiency difficult. The aim of this study was to investigate the effect of sex, a...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.07.003

    authors: Franchi F,Biguzzi E,Martinelli I,Bucciarelli P,Palmucci C,D'Agostino S,Peyvandi F

    更新日期:2013-08-01 00:00:00

  • Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications.

    abstract:INTRODUCTION:Portal vein thrombosis (PVT) is a well-known complication in patients with liver cirrhosis (LC). The aim of this study is to investigate the outcomes of cirrhotic patients with PVT treated with low-molecular-weight heparin (LMWH). METHOD:Ninety-one LC patients with PVT were treated with dalteparin or enox...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2018.01.032

    authors: Kwon J,Koh Y,Yu SJ,Yoon JH

    更新日期:2018-03-01 00:00:00

  • D-dimer specific monoclonal antibodies react with fibrinogen aggregates.

    abstract::Human fibrinogen exposed to 46.5 degrees C was subjected to gel permeation chromatography. The protein eluted in two distinct peaks. The first peak appeared in the void volume containing soluble fibrinogen aggregates, while the other peak represented monomeric fibrinogen. In contrast to the monomeric peak material, th...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(96)00063-1

    authors: Bennick A,Haddeland U,Brosstad F

    更新日期:1996-04-15 00:00:00

  • Cloning, purification and characterization of a recombinant protease with novel thrombolytic activity in human plasma and rat thrombosis models.

    abstract:BACKGROUND:There is a need to identify and develop novel thrombolytic agents that can directly digest fibrin clots from various biological resources. OBJECTIVE:To clone, express, purify, and characterize a recombinant protease named rvFMP capable of cleaving fibrinogen, fibrin polymer, and cross-linked fibrin in human...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2020.04.040

    authors: Lim DS,Park JE,Park JW,Cho YH,Park JK,Lee JS

    更新日期:2020-07-01 00:00:00

  • Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial.

    abstract:BACKGROUND:The methodology of thromboprophylaxis post minimally invasive esophagectomy (MIE) is unclear. Thus, we compared the efficacy and safety of fondaparinux and nadroparin on the prophylaxis of venous thromboembolism (VTE) after MIE. MATERIALS AND METHODS:We conducted a randomized, double-blind, treatment-contro...

    journal_title:Thrombosis research

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.thromres.2018.04.001

    authors: Song J,Xuan L,Wu W,Shen Y,Tan L,Zhong M

    更新日期:2018-06-01 00:00:00

  • Discovering novel risk factors for venous thrombosis: a candidate-gene approach.

    abstract::The candidate-gene approach can be used to locate and identify genetic variations that are associated with a particular phenotype. This gene-centric approach assumes that there exists important genetic variation within genes that can influence health. Identifying known genes which are candidates for the phenotype of i...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/S0049-3848(09)70139-2

    authors: Smith NL,Rice KM,Lumley T,Heckbert SR,Psaty BM

    更新日期:2009-01-01 00:00:00

  • Thromboprophylaxis in acutely ill medical patients: results of a survey among Italian physicians.

    abstract:AIMS:acutely ill medical patients are at increased risk of venous thromboembolism (VTE) and often require thromboprophylaxis, but patient selection and adequate therapeutic decisions may be difficult due to the heterogeneity and the complexity of this population. We conducted a survey among a large cohort of Italian ph...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2014.06.013

    authors: Dentali F,Pomero F,La Regina M,Orlandini F,Turato S,Mazzone A,Nozzoli C,Fontanella A,Ageno W,Agnelli G,Campanini M

    更新日期:2014-09-01 00:00:00

  • Systematic review of anticoagulant treatment of catheter-related thrombosis.

    abstract::Central venous catheter-related thrombosis (CRT) is a complication seen in patients requiring long-term intravenous access. Treatment of CRT is not standardized and international guidelines for treatment are based on extrapolation of evidence from lower extremity thrombosis. We performed a systematic review of the lit...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/j.thromres.2015.08.020

    authors: Baumann Kreuziger L,Onwuemene O,Kolesar E,Crowther M,Lim W

    更新日期:2015-12-01 00:00:00

  • Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection).

    abstract::RheothRx Injection, an aqueous solution of a nonionic block copolymer (poloxamer 188) formulated for intravenous administration, was investigated as an inhibitor of red blood cell (RBC)-induced platelet aggregation at plasma concentrations of 0.05-5mgmL-1. Platelet aggregation was determined by measuring the fall in s...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(95)00134-d

    authors: Armstrong JK,Meiselman HJ,Fisher TC

    更新日期:1995-09-15 00:00:00

  • CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.

    abstract:INTRODUCTION:Information regarding any possible additional effect of genetic variants other than CYP2C19*2 on platelet reactivity in patients undergoing percutaneous coronary intervention (PCI), while on dual antiplatelet therapy, is sparse. MATERIALS AND METHODS:Genotyping for CYP2C19*2, CYP2C19*17, CYP2C9*3, CYP2B6*...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.thromres.2011.07.022

    authors: Kassimis G,Davlouros P,Xanthopoulou I,Stavrou EF,Athanassiadou A,Alexopoulos D

    更新日期:2012-04-01 00:00:00

  • Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.

    abstract:BACKGROUND:The level of platelet reactivity (PR) inhibition obtained after P2Y12-ADP receptor antagonist loading dose (LD) is associated with the ischemic and bleeding risk following percutaneous coronary intervention (PCI) in acute coronary syndromes (ACS). OBJECTIVE:We aimed to evaluate the level of PR inhibition ac...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2013.04.030

    authors: Laine M,Toesca R,Berbis J,Frere C,Barnay P,Pansieri M,Peyre JP,Michelet P,Bessereau J,Camilleri E,Helaf O,Camaleonte M,Paganelli F,Dignat-George F,Bonello L

    更新日期:2013-07-01 00:00:00

  • Evidence of a phospholipid binding species within human fibrinogen preparations.

    abstract::Fibrinogen has been reported to interact with phospholipid; however, the properties of this binding interaction have not been characterized. Purified preparations of human fibrinogen bound to small unilamellar vesicles containing phosphatidylserine (PS) as measured by light scattering and radioisotope filtration. Bind...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(99)00058-4

    authors: Cunningham MT,Citron BA,Koerner TA

    更新日期:1999-09-15 00:00:00

  • The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: A prospective observational study.

    abstract:INTRODUCTION:Endothelial dysfunction plays an essential role in the pathogenesis of sepsis. The study aimed to illustrate the associations between the dynamic change (from day 1 to day 7) in biomarker concentration of endothelial dysfunction and outcomes in severe sepsis and septic shock in the intensive care unit (ICU...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2018.09.059

    authors: Fang Y,Li C,Shao R,Yu H,Zhang Q

    更新日期:2018-11-01 00:00:00

  • Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry.

    abstract:INTRODUCTION:Ticagrelor and prasugrel are recommended as first line therapy in patients with acute coronary syndromes (ACS). However, patients with anemia are commonly treated with clopidogrel in routine clinical practice. The RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infar...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2018.05.024

    authors: Guerrero C,Garay A,Ariza-Solé A,Formiga F,Raposeiras-Roubín S,Abu-Assi E,D'Ascenzo F,Kinnaird T,Manzano-Fernández S,Alegre O,Sánchez-Salado JC,Lorente V,Templin C,Velicki L,Xanthopoulou I,Cerrato E,Rognoni A,Boccuzzi G

    更新日期:2018-07-01 00:00:00

  • Changes in the fibrinolytic system in patients with peripheral arterial occlusive disease undergoing percutaneous transluminal angioplasty.

    abstract::We have investigated fibrinolytic parameters in 33 patients with peripheral arterial occlusive disease (PAOD) before and 6, 24, and 48 hours after percutaneous transluminal angioplasty (PTA) as well as in 35 gender-matched healthy controls, whose mean age was not significantly different from the mean age of the patien...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(99)00002-x

    authors: Roller RE,Janisch S,Carroll V,Kvas E,Pilger E,Binder BR,Wojta J

    更新日期:1999-05-15 00:00:00

  • Modulation of megakaryopoiesis and platelet production during inflammation.

    abstract::Megakaryocytes (MKs) are widely known as the progenitor cells of platelets. These large, polyploid cells are a derivative of the hematopoietic stem cell (HSC), and reside in the bone marrow, lining blood vessel walls where they release their platelet progeny into circulation. Although little is known about how MKs dif...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/j.thromres.2019.05.008

    authors: Couldwell G,Machlus KR

    更新日期:2019-07-01 00:00:00

  • An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery.

    abstract:INTRODUCTION:We conducted this prospective study in order to investigate the hypotheses that an alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass (CPB) surgery and major abdominal surgery and that the levels of fibrin degradation products digested by polymorphonucle...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.thromres.2006.07.009

    authors: Gando S,Kameue T,Sawamura A,Hayakawa M,Hoshino H,Kubota N

    更新日期:2007-01-01 00:00:00

  • Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.

    abstract::The potent inhibitor of platelet cAMP phosphodiesterase (PDE) HL 725 (9,10-Dimethoxy-2-mesitylimino-3-methyl-3, 4,6,7-tetrahydro-2H-pyrimido(6,1-A)-isoquinoline-4-one-hydrochloride), was examined for its effects on human and rat platelet aggregation. Strong inhibitory effects are seen on collagen-induced platelet aggr...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(87)90376-8

    authors: Agarwal KC,Buckley RS,Parks RE Jr

    更新日期:1987-07-15 00:00:00

  • Warfarin-induced factor VII deficiency and the bleeding time.

    abstract::The effect of warfarin-induced factor VII deficiency on the skin bleeding time was investigated in 10 consecutive patients with mean prothrombin times of 33 sec and factor VII levels of 7%. Bleeding times in all but one subject were entirely within the normal range. We conclude that warfarin administration, even to th...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(83)90243-8

    authors: Green D,Ts'ao CH

    更新日期:1983-02-15 00:00:00

  • Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies.

    abstract::Endothelial cell activation or damage is believed to play a key role in preeclampsia (PE) and may underlie the hemostatic changes observed in this syndrome. The aim of this study was to evaluate a relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies. We measured the plasma l...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2008.02.007

    authors: Catarino C,Rebelo I,Belo L,Rocha S,Castro EB,Patricio B,Quintanilha A,Santos-Silva A

    更新日期:2008-01-01 00:00:00

  • Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience.

    abstract:INTRODUCTION:The epidemiology of tamoxifen and venous thromboembolism (VTE) is not well understood, and most data on tamoxifen toxicity are from adjuvant clinical trials. This study examined the relationship between the duration of tamoxifen use in female patients with breast cancer and the risk of VTE in a large popul...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2011.11.025

    authors: Onitilo AA,Doi SA,Engel JM,Glurich I,Johnson J,Berg R

    更新日期:2012-07-01 00:00:00

  • Endogenous forms of fibrinogen in Hep G2 cells.

    abstract::The three polypeptide chains of fibrinogen, A alpha, B beta and gamma chain, are synthesized on separate polysomes. Fully formed fibrinogen is a six chain, disulfide-linked, dimeric molecule with a molecular weight of 340kDa. Previous pulse-chase studies with L-35 S methionine using the human hepatocellular carcinoma ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(87)90290-8

    authors: Yu S,Kong V,Kudryk B,Redman C

    更新日期:1987-04-15 00:00:00

  • Management of thrombocytopenia in cancer.

    abstract::Thrombocytopenia is a common finding in cancer patients and can have different and/or multifactorial pathogenesis. While in solid tumors it occurs often as a consequence of chemotherapy treatment, it is frequently observed at diagnosis in patients with hematological malignancies being aggravated to a potentially life-...

    journal_title:Thrombosis research

    pub_type: 杂志文章,评审

    doi:10.1016/j.thromres.2018.02.001

    authors: Castaman G,Pieri L

    更新日期:2018-04-01 00:00:00

  • Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.

    abstract:BACKGROUND:Sampling small volumes of blood may be necessary, particularly in pediatric patients, or in case of difficult or recurrent venipunctures. METHODS:Routine hemostasis test results evaluated in partial- and full-draw evacuated polymer tubes obtained in 4 centers were compared. RESULTS:No relevant discrepancy ...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2010.08.029

    authors: Toulon P,Abecassis L,Smahi M,Ternisien C

    更新日期:2010-12-01 00:00:00

  • Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma.

    abstract::The zymogen form of circulating Factor VII activating protease (FSAP) is activated by histones that are released as a consequence of tissue damage or excessive inflammation. This is likely to have consequences in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2019.08.016

    authors: Rut W,Nielsen NV,Czarna J,Poreba M,Kanse SM,Drag M

    更新日期:2019-10-01 00:00:00

  • Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients.

    abstract:BACKGROUND:Muromonab-CD3 is a murine monoclonal antibody (MoAb) that is used in the prophylaxis and treatment of acute graft rejection. Activation of coagulation and fibrinolysis following anti-CD3 administration have been reported in some patients to lead to irreversible intragraft thrombosis. DESIGN AND METHODS:We h...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(01)00396-6

    authors: Lozano M,Oppenheimer F,Cofan F,Rosinyol L,Mazzara R,Escolar G,Ordinas A

    更新日期:2001-12-15 00:00:00

  • Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism.

    abstract:BACKGROUND:Systemic thrombolysis rapidly improves right ventricular (RV) dysfunction in patients with acute pulmonary embolism (PE) but is associated with major bleeding complications in up to 20%. The efficacy of low-dose, catheter-directed ultrasound-accelerated thrombolysis (USAT) on the reversal of RV dysfunction i...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2011.05.014

    authors: Engelhardt TC,Taylor AJ,Simprini LA,Kucher N

    更新日期:2011-08-01 00:00:00

  • Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.

    abstract:BACKGROUND:Variability in platelet response to clopidogrel and its clinical relevance have been well described. However, the underlying mechanisms remain unclear. Recently, the T744C polymorphism of the P2Y12 receptor gene has been associated with enhanced platelet aggregation in healthy volunteers, suggesting a possib...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2007.01.012

    authors: Cuisset T,Frere C,Quilici J,Morange PE,Saut N,Lambert M,Camoin L,Vague IJ,Bonnet JL,Alessi MC

    更新日期:2007-01-01 00:00:00

  • Efficacy and safety of clopidogrel in children with diarrhea associated hemolytic uremic syndrome.

    abstract:INTRODUCTION:Hemolytic uremic syndrome is a thrombotic microangiopathy. Clopidogrel, a recently developed platelet aggregation inhibitor, has not been previously reported as a treatment for this illness. Our study's objective was to explore the efficacy and safety of clopidogrel in children with diarrhea associated hem...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.thromres.2012.05.017

    authors: Seltz LB,Bakel LA,Tiehen J,Gao D,Cadnapaphornchai MA,Lum G,Ford D

    更新日期:2012-09-01 00:00:00

  • Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay.

    abstract:INTRODUCTION:Patients with stable coronary artery disease (CAD) are at risk of arterial thrombosis causing myocardial infarction. Detection of global haemostatic markers of hypercoagulability and hypofibrinolysis may be important for risk stratification and individualised treatment. We examined overall haemostatic pote...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2013.03.015

    authors: Reddel CJ,Curnow JL,Voitl J,Rosenov A,Pennings GJ,Morel-Kopp MC,Brieger DB

    更新日期:2013-05-01 00:00:00